This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

Oncology nurses and APPs are key players in patient education on precision medicine.

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

In 2021, immune checkpoint inhibitors were used by 12.1% of patients with cancer—however, these agents represent 36.2% of all oncology medication costs. Although novel immunotherapies hold promise for ...

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals. In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 ...